- Himax Technologies and WAFERLOCK Corporation recently announced that Himax’s WiseEye palm vein biometric authentication has been integrated into WAFERLOCK’s now-commercial L322 palm vein smart lock, bringing contactless, on-device AI security to residential and smart-building access control.
- This launch showcases Himax’s ability to embed ultralow power endpoint AI and privacy-focused biometrics into real-world smart home products through ecosystem partnerships.
- Next, we’ll examine how commercial deployment of WiseEye in WAFERLOCK’s palm vein smart lock could reshape Himax’s investment narrative around endpoint AI.
AI is about to change healthcare. These 42 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
Himax Technologies Investment Narrative Recap
To own Himax today, you need to believe its traditional display IC base can be steadily supplemented by newer product lines like WiseEye endpoint AI, AR components, and CPO, while margins stabilize despite cost pressures and demand swings. The WiseEye-powered WAFERLOCK L322 launch directly supports the IoT and smart access catalyst but does not fundamentally change near term execution risk around sluggish demand, pricing pressure, and exposure to tariffs and macro uncertainty.
Among recent announcements, the Q3 2026 guidance for 7% to 11% quarter over quarter revenue growth is particularly relevant, because it provides a near term check on how quickly newer businesses such as WiseEye can offset volatility in core display IC segments. Investors watching the L322 commercialization may track whether any contribution shows up in non-driver IC growth and helps counterbalance pressure from cautious automotive and consumer electronics customers.
Yet while WiseEye’s progress is encouraging, investors should still be aware of how rising operating expenses and margin pressure could interact with...
Read the full narrative on Himax Technologies (it's free!)
Himax Technologies’ narrative projects $1.8 billion revenue and $324.3 million earnings by 2029.
Uncover how Himax Technologies' forecasts yield a $30.20 fair value, a 117% upside to its current price.
Exploring Other Perspectives
Some of the lowest estimate analysts paint a tougher picture for Himax than this WiseEye news might suggest, even though they still projected revenue climbing to about US$1.4 billion and earnings near US$305 million by 2029, before this announcement. If you think palm vein locks and other endpoint AI uses could offset their concerns about structural pressure on core display drivers, it is worth comparing your own expectations with these more cautious assumptions.
Explore 6 other fair value estimates on Himax Technologies - why the stock might be worth less than half the current price!
Decide For Yourself
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Himax Technologies research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
- Our free Himax Technologies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Himax Technologies' overall financial health at a glance.
Want Some Alternatives?
Every day counts. These free picks are already gaining attention. See them before the crowd does:
- Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
- We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
- Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com